Abstract. A recombinant protein, rLdccys1, which was produced by expression of the gene encoding a 30 kDa cysteine proteinase from Leishmania (Leishmania) chagasi, was used for detection of antibodies in sera from patients with active visceral leishmaniasis (VL) in enzyme-linked immunosorbent assays. Analysis of the predicted amino acid sequence of rLdccys1 showed that it contains all the characteristics of a cysteine proteinase. The ability of the protein to react with sera from humans with VL was also shown by Western blotting. The sensitivity for detection of specific antibodies to L. (L.) chagasi bodies using rLdccys1, L. (L.) chagasi promastigote lysates, and amastigote lysates was 80%, 98%, and 99%, respectively. No cross-reactivity between rLdccys1 and Chagas disease was observed, and there was little positive reactivity with sera from patients with cutaneous leishmaniasis and tuberculosis, compared with promastigote and amastigote extracts. Our findings indicate that rLdccys1 from L. (L.) chagasi constitutes a potential tool for the diagnosis of American VL.
INTRODUCTION
Leishmaniasis comprises a group of diseases caused by protozoan parasites of the Leishmania genus that includes cutaneous, mucocutaneous and visceral leishmaniasis. 1 Visceral leishmaniasis (VL) is caused mainly by Leishmania (Leishmania) donovani in Indian and east Africa, Leishmania (L.) infantum in the Mediterranean area, and Leishmania (L.) chagasi in South America. The most severe form of the disease affects 500,000 people worldwide. 2 In Brazil, rural to urban migration contributes to the spreading of VL in towns and suburbs of large cities. 3, 4 The disease symptoms include irregular fever, splenomegaly, hepatomegaly, anemia, weight loss, and pancytopenia, and may lead to death if untreated. Development of clinical disease may be dependent on other factors including malnutrition, use of immunosuppressive drugs, and, especially, co-infection with human immunodeficiency virus. [5] [6] [7] Routine diagnosis of VL has been based on the visualization of the parasite in bone marrow smears or splenic aspirates; however, this method is limited by a low sensitivity. 8 Serologic diagnosis of VL is based on different methods of antibody detection that include the direct agglutination test, 9 the indirect immunofluorescence test, 10 immunoblot analysis, [11] [12] [13] [14] and the enzyme-linked immunosorbent assay (ELISA). [15] [16] [17] [18] However, use of whole parasite extracts in these serologic tests is limited because of assay reproducibility and specificity mainly due to the cross-reactivity with other diseases such as Chagas disease, cutaneous leishmaniasis, and tuberculosis. [18] [19] [20] To obtain a specific diagnosis for VL, the following purified and recombinant Leishmania antigens have been used in serologic tests: SLA, gp63, rK39, rGBP, H2A, H2B, rLACK, rP20, rPSA-2, and A2. [21] [22] [23] [24] [25] [26] [27] [28] [29] Comparative evaluation of ELISAs using these antigens showed that several of them are suitable in the diagnosis of Mediterranean VL. 30 Leishmania cysteine proteinases have been used as targets for vaccines, [31] [32] [33] chemotherapy, 34, 35 and serodiagnosis of cutaneous leishmaniasis and VL. 36, 37 Previous studies from our laboratory demonstrated the implication of a 30 kDa cysteine proteinase from L. (L.) chagasi (p30) in partially protective cellular immune responses against homologous infection in BALB/c mice. 32 In the present study, we have expressed the gene encoding the p30 antigen from L. (L.) chagasi, Ldccys1, in Escherichia coli and tested the recombinant protein (rLdccys1) for use in serodiagnosis of American VL. In L. (L.) chagasi, the Ldccys1 gene is organized as a multicopy gene tandemly arranged and expressed in promastigote and amastigote forms. 38 The amino acid sequence shows high identity, 78%, 79%, and 76%, to cysteine proteinases from Leishmania (L.) mexicana cpb18, Leishmania (L.) pifanoi Lpcys2, and Leishmania (L.) major cathepsin L-like protease, respectively, and also shows all conserved characteristic residues of cysteine proteinases. Sera from patients living in areas of Brazil endemic for VL, healthy controls, and from patients with other diseases were used to determine the sensitivity and specificity of the recombinant Ldccys1 antigen in comparison with crude L. (L.) chagasi lysates in ELISAs.
MATERIALS AND METHODS
Parasites. Eight-week-old female golden hamsters were obtained from breeding stocks maintained at the Universidade of Campinas (Sã o Paulo, Brazil). All animal procedures were reviewed and approved by the Ethical Committee for Animal Care at the Universidade Federal de Sã o Paulo Escola Paulista de Medicina. The L. (L.) chagasi strain used (MHOM/BR/1972/LD) was characterized and kindly provided by Dr. J. J. Shaw (Instituto Evandro Chagas, Belém, Pará, Brazil) and maintained as amastigotes by inoculation of hamsters by the intraperitioneal route. Two months after infection, the hamsters were killed and the spleens were homogenized, treated with 0.2% saponin for 10 minutes, and centrifuged at 1,400 × g for 5 minutes for isolation of amastigotes. The resulting pellet was resuspended in phosphatebuffered saline (PBS), centrifuged at 250 × g for 5 min, the supernatant was centrifuged at 1,400 × g for 5 minutes, and the pellet was resuspended in PBS. The suspension was agitated for 3 hours at room temperature and centrifuged at 1,400 × g for 5 minutes. The final pellet containing purified amastigotes was frozen at −20°C until use.
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Isolation of genomic DNA and polymerase chain reaction (PCR) amplification of the L. (L.) chagasi cysteine proteinase gene 1 (Ldccys1). Leishmania (L.) chagasi genomic DNA was extracted from 1 × 10 9 amastigotes as previously described. 40 Amplification of the L. (L.) chagasi Ldccys1 gene was performed using primers corresponding to its open reading frame (ORF), previously published in GeneBank. 41 The 5Ј end primer (5Ј-TGC GGG ATC CCC ATG GCG ACG TCG AGG-3Ј) and the 3Ј end primer (5Ј-CGA TGA ATT CCC CTA CGT GTA CTG GCA-3Ј) containing Bam HI and Eco RI restriction site sequences, respectively, were used for directional cloning. The PCR amplification was carried out using 100 ng of L. (L.) chagasi genomic DNA and 100 pmol of each primer in a mixture containing 0.2 mM of each dNTP, 10 mM Tris-HCl, pH 9.0, 1 mM MgCl 2 , 50 mM KCl, and 1 unit of Taq DNA polimerase in a final volume of 50 L. Amplification conditions were 30 cycles at 94°C for 1 minute, 40°C for 2 minutes, and 72°C for 2 minutes. The PCR products were gel purified (Geneclean II kit; Bio-Rad Laboratories, Hercules, CA), digested with Bam HI and Eco RI, and cloned in the Bam HI and Eco RI sites of plasmid pUC18. The DNA sequencing was carried out according to the dideoxy-chain method in an ABI377 automatic sequencer (Applied biosystmes, Foster City, CA).
Expression and purification of the recombinant cysteine proteinase (rLdccys1). The PCR product corresponding to the ORF of the Ldccys1 gene was subcloned into the Bam HI and Eco RI restriction sites of the pHis-parallel 3 expression vector in frame with an amino-terminal six histidine tag. 42 The recombinant plasmids were used to transform E. coli BL21(DE3) and protein expression was carried out by inoculating 500 mL of Luria Bertani medium containing 100 g/mL of ampicilin with a 25 mL overnight bacterial culture. The suspension was incubated on a rotatory shaker at 37°C until log phase (absorbance at 600 nm ‫ס‬ 0.6) was reached. Protein expression was then induced with 0.2 mM isopropyl-␤-Dthiogalactopyranoside for an additional 3 hours at 37°C. After growth, the recombinant bacteria were centrifuged at 4,000 × g for 10 minutes and the recombinant antigen was purified from the insoluble inclusion bodies by affinity chromatography using a Ni-NTA Superflow agarose matrix (Qiagen, Valencia, CA) according to the method of Skeiky and others. 43 Purified protein was analyzed by sodium dodecyl sulfatepolyacrylamide gel electrophoesis (SDS-PAGE) and Western blotting using a previously described monoclonal antibody (2E5D3) directed against a 30 kDa cysteine proteinase of L. (L.) amazonensis that cross-reacts with a 30 kDa antigen of L. (L.) chagasi amastigotes. 31, 32 Human sera. Sera used in this study were classed as normal, active cases of VL, and other diseases. Human VL serum samples were collected from 131 individuals living in areas of Brazil endemic for VL. All patients had a VL diagnosis confirmed by the identification of amastigotes in bone marrow tissue, an indirect immunofluorescence reaction, a positive ELISA result, and showed clinical symptoms of VL: fever, splenomegaly, anemia, coughing, and wasting. Normal human sera were collected from 74 individuals living in a nonendemic area. Sera from individuals with other diseases included confirmed cases of cutaneous leishmaniasis (n ‫ס‬ 26), Chagas disease (n ‫ס‬ 35), and tuberculosis (n ‫ס‬ 12).
Western blotting analysis. Extracts from L. (L.) chagasi
amastigotes and promastigotes and the recombinant protein were subjected to electrophoresis on a 12% SDS-polyacrylamide gel and transferred to nitrocellulose membranes as described by Towbin and others. 44 Membranes were blocked with 5% powdered skim milk in PBS and incubated for 1 hour with monoclonal antibody 2E5D3 and VL human sera diluted 1:100. The strips were then washed in 0.05% Tween 20 in PBS and incubated with peroxidase-conjugated anti-mouse and anti-human secondary antibodies, and developed with diaminobenzidine and H 2 O 2 .
Ezyme-linked immunosorbent assay. Microtiter plates (high-binding Costar plates; Corning, Inc., Corning, NY) were coated with the recombinant protein (200 ng/well) or L. (L.) chagasi extracts from amastigotes and promastigotes (100 ng/well) in coating buffer (0.05 M Na 2 CO 3 /NaHCO 3 , pH 9.6). The plates were incubated overnight at 4°C and then blocked with 5% powdered skim milk in PBS for 1 hour. Human sera diluted 1:500 were added and incubated for 1 hour at room temperature. After three washes with 0.05% Tween 20 in PBS, anti-human IgG horseradish peroxidase conjugate (Bio-Rad Laboratories) (diluted 1:1,000) was added and incubated for 1 hour at 37°C. The plates were washed three times in 0.05% Tween 20 in PBS and the reaction was developed with 0. 41 we amplified a 1.3 kb fragment by the PCR. The nucleotide sequence analysis of the 1.3 kb fragment showed 99.8% identity with the published sequence of the Ldccys1 gene, with an ORF encoding a protein that contained all the characteristics of a cysteine proteinase as previously shown by Omara-Opyene and Gedamu 41 and observed by the deduced amino acid sequence of the 1.3 kb fragment shown in Figure 1 . It contains the conserved cysteine and histidine residues at positions 150 and 287, respectively, which are present in the catalytic domain of cysteine proteinases. Glycine, which is involved in substrate binding in papain, is also present at position 148. In addition, another amino acid residue important in catalysis, asparagine, is present at position 307. The Ldccys1 protein is composed of pre-region and pro-region followed by a mature protease core and a C-terminal extension. The pre-region contains the hydrophobic amino acid represented by residues 1-37. The pro-region is cleaved between amino acid residues 124 and 125, generating an alanine as in the case of other cysteine proteinases. In the C-terminal region, Ldccys1 contains 10 conserved cysteine residues present in other cysteine proteinases. 45 Expression and purification of the recombinant cysteine proteinase. The 1.3 kb fragment, which corresponds to the ORF of the Ldccys1 gene, was cloned into the pHis parallel 3 expression vector in frame with a six-histidine tag. Expression of the Ldccys1 gene in E. coli resulted in a recombinant 47 kDa protein that was solubilized in 8 M urea and extracted on a nickel column, and its purity was demonstrated by SDS-PAGE. Figure 2A Of 131 sera from patients with active VL, 80% reacted with rLdccys1, while 98% and 99% were reactive with promastigote and amastigote extracts, respectively (Figure 4) .
The specificity of the rLdccys1 was evaluated using sera from healthy controls and from patients with other diseases including cutaneous leishmaniasis, tuberculosis, and Chagas disease (Figure 4 ). The rLdccys1 antigen was very specific (96%), showing no cross-reactivity with sera from patients with Chagas disease, and very low rates of positive reactions with sera from patients with cutaneous leishmaniasis (3%, n ‫ס‬ 26) and tuberculosis (8%, n ‫ס‬ 12), and only four falsepositive results in sera from 74 healthy controls. In contrast, amastigote and promastigote extracts showed high rates of cross-reactivity with sera from patients with cutaneous leishmaniasis (65% and 80%, respectively, n ‫ס‬ 26), tuberculosis (83% for both extracts, n ‫ס‬ 12), and Chagas disease (14% and 34%, respectively, n ‫ס‬ 35). Table 1 shows the sensitivity, specificity, positive predictive value, and negative predictive value of the three antigens used in the ELISAs. The data demonstrate that the rLdccys1 antigen was significantly more specific than L. (L.) chagasi extracts for diagnosis of VL by ELISA.
DISCUSSION
The 30 kDa cysteine proteinase of L. (L.) chagasi was first implicated in cellular immune responses mediated by Th1 cells partially protective against homologous infection in BALB/c mice. 32 The present work shows the antigenicity of this cysteine proteinase for humoral responses in clinically and parasitologically confirmed cases of human VL by use of a recombinant protein obtained after expression of the previously cloned and characterized Ldccys1 gene. 41 The recombinant Ldccys1 antigen was obtained by expression of the Ldccys1 gene in the pHis vector, resulting in a 47 kDa protein whose predicted amino acid sequence analysis showed that it shares 99% identity with the Ldccys1 cysteine proteinase from L. (L.) chagasi amastigotes (Figure 1) . Reactivity of Previous screening using 10 individual sera from patients with VL and the recombinant protein in an ELISA showed that the reactivity of rLdccys1 is comparable with that exhibited by promastigote extract to a dilution of 1:1,600 ( Figure  3A ). This demonstrates the feasibility of using this antigen for antibody detection in sera from patients with VL. Immunoblotting of L. (L.) chagasi promastigote and amastigote extracts against sera from patients with VL identified several reactive antigens, some of them common to both parasite forms, and showed that the 30 kDa cysteine proteinase is recognized by sera from patients with VL ( Figure 3B (Figure 1 ). This result is consistent with previous data showing the high identity among cysteine proteinases expressed in Leishmania. 45, 46 The level of sensitivity with rLdccys1 was comparable with that obtained with rCPB (76%), strengthening the identity of these cysteine proteinases, and supporting the similarity of L. (L.) chagasi and L. (L.) infantum, which has been demonstrated by genotypic relationships within the L. (L.) donovani complex. 47, 48 Antibodies to rLdccys1 were detected in 80% of the samples from humans with active VL. This value is comparable to those obtained by use of the recombinant L. (L.) donovani A2 antigen by Carvalho and others 29 (77%) in sera from Brazilian patients with symptomatic VL and by Ghedin and others 28 in sera from Sudanese (80%) or Indian patients (60%), and is lower than the level of sensitivity reported with other Leishmania recombinant antigens. 30 Conversely, the specificity of rLdccys1 is high and comparable to that observed with recombinant proteins analyzed, 25, 49 and is consistent when one considers infectious diseases that occur in same VL-endemic areas and whose cross-reactivity with Leishmania is well documented. Moreover, the spectrum of absorbance values obtained with rLdccys1 is comparable to that obtained with promastigote and amastigote extracts (70%, 84%, and 66% of VL sera showed an optical density greater than 1 with rLdccys1, promastigote, and amastigote lysates, respectively), allowing easy interpretation of ELISA results. 
